Breaking News

Thermo Fisher, Daiichi Sankyo to Co-Develop CDx

Agreement aims to identify HER2 gene mutations using Oncomine Dx Target Test for patients with Non-Small Cell Lung Cancer

By: Contract Pharma

Contract Pharma Staff

Thermo Fisher Scientific and Daiichi Sankyo have expanded their partnership to co-develop a companion diagnostic (CDx) using Thermo Fisher’s next-gen sequencing (NGS)-based Oncomine Dx Target Test. The CDx will be designed to identify non-small cell lung cancer (NSCLC) patients with human epidermal growth factor receptor 2 (HER2) mutations who may be eligible for Enhertu, a HER2 directed antibody drug conjugate (ADC), currently in Phase II development for HER2 mutated or HER2 overexpressing NSCL...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters